Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

April 2, 2019

Study Completion Date

April 2, 2019

Conditions

Leukemia

Interventions

DRUG

Ruxolitinib

"Starting dose level for Part 1: 5 mg by mouth twice a day for a 28 day cycle.~Starting dose level for Part 2: Maximum tolerated dose from Part 1."

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston